The Sooner, the Better: Planning for FDA Pre-IND Review of COVID-19 Studies

COVID-19 is a perfect example of a novel disease for which there is an urgent need for both vaccines and therapies. To help reduce the application review timelines, the FDA issued guidance for Pre-IND meeting requests in May. We summarize the recommendations and provide advice from our regulatory affairs team.

Continue Reading The Sooner, the Better: Planning for FDA Pre-IND Review of COVID-19 Studies